SAN FRANCISCO, June 7, 2008 (PRIME NEWSWIRE) -- XOMA Ltd. (Nasdaq:XOMA) announced today at the Federation of Clinical Immunology Societies 2008 FOCIS Annual Meeting that a study of XOMA 052 in a mouse model of rheumatoid arthritis demonstrated that XOMA 052 significantly reduced the bone and cartilage destruction caused by collagen-induced arthritis and effectively prevented and treated disease as assessed by a standard measure of inflammation and swelling. A poster detailing the data titled “Efficacy of XOMA 052 Anti-IL-1 beta Antibody in the DBA/1 Mouse Collagen-Induced Arthritis Model” is being presented at the meeting today at 5:45 p.m. Eastern time.
